Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield MI formulary Coverage Updat…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - MichiganPolicy N/A

    2026 Healthy Value Enhanced Comprehensive Formulary (Medicare Part D) — Coverage Criteria

    Customize your policy alerts

    Sign up for all blue cross blue shield - michigan policy alerts

    Know when blue cross blue shield - michigan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Describes the drugs covered, restrictions (prior authorization, step therapy, quantity limits), and how members or prescribers can request exceptions for Medicare Plus Blue Group PPO and Prescription Blue Group PDP members.

    Policy Summary
    PayerBlue Cross Blue Shield - Michigan
    Policy2026 Healthy Value Enhanced Comprehensive Formulary — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization from the plan before dispensing drugs marked 'PA' to avoid denial of coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    06/01/2026Formulary effective date
    90-day90-day supply guidance
    31 daysTemporary transition supply
    ~manyPA / EX flags present

    Coverage Criteria

    General formulary coverage and exception criteria

    Covered when ALL of the following are met

    Coverage preconditions: Drug is listed on the plan formulary; prescribed for a medically necessary indication; filled at an in-network pharmacy; plan rules (prior authorization, step therapy, quantity limits) are followed.

    Based on formulary description and plan rules

    Exception approvals: If the drug is not on formulary or a restriction would apply, coverage may be granted via exception if the prescriber documents medical reasons why alternatives or restrictions would not be as effective or would cause adverse effects.

    Exception decision is generally within 72 hours (24 hours if expedited).

    Formulary coverage stance

    Coverage and use restrictions as noted on the formulary table

    Policy Summary
    PayerBlue Cross Blue Shield - Michigan
    Policy2026 Healthy Value Enhanced Comprehensive Formulary — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization from the plan before dispensing drugs marked 'PA' to avoid denial of coverage.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Formulary EntriesProvider Actions and Documentation RequirementsBackgroundDefinitions and LegendStep Therapy RulesQuantity Limits (QL) by ProductRevision History
    Formulary tiering and supply rules: Drugs are assigned to tiers (1-5) which determine cost-sharing and supply limits; Tier 1-4 often allow 90-day supply, Tier 5 limited to 31 days.

    See Evidence of Coverage for member cost-share details.

    Prior authorization and specialty programs: Certain drugs require prior authorization (PA); antineoplastics and oncology supportive care require prior authorization through the Oncology Value Management (OVM) program administered by OncoHealth; PA must be obtained before dispensing.

    Failure to obtain PA may result in non-coverage.

    Quantity limits and non-extended day supply: Many drugs have quantity limits (QL) expressed as EA or ML per specified days; some drugs are flagged NDS (Non-Extended Day Supply) restricting supply (e.g., most opioids and benzodiazepines).

    Specific QL and NDS rules are shown on formulary rows.

    Formulary coverage by tier with utilization controls

    Coverage determined by tier assignment and listed Requirements/Limits

    Formulary coverage: Drug is covered according to assigned tier unless marked with PA or EX; applicable quantity limits (QL) and step therapy (ST) must be followed as shown in the Requirements/Limits column.

    No additional clinical eligibility criteria are provided in these table excerpts.

    Formulary coverage entries

    Coverage shown as formulary tier with attached utilization management requirements

    Formulary entry: Each formulary row lists the drug's tier and, where applicable, Requirements/Limits such as Quantity Limits (QL), Prior Authorization (PA), Oncology Visit Management (OVM), and Step Therapy (ST). Coverage is contingent on meeting those administrative requirements.

    Specific clinical PA forms or full clinical criteria are not included in these excerpted rows.

    Formulary coverage with administrative controls

    Drugs listed are on the formulary and have the following coverage conditions as shown per row

    Formulary row conditions: Coverage for the listed drug/strength is governed by the tier assignment and any Requirements/Limits noted on the row (examples: PA, QL with exact allowed amount/timeframe, OVM for oncology agents, ST where indicated).

    Refer to the formulary row for the exact Requirements/Limits for that product and strength.

    Formulary table coverage (informational)

    Coverage follows formulary table annotations; provider must follow PA and QL where indicated.

    Table-based coverage rules: Drug is subject to the formulary tier, quantity limits, prior authorization, step therapy, or exclusion as specified in the table row for that exact product and strength.

    If a row indicates EX the product is not normally covered; if PA or QL are shown, prescribers must obtain approval or adhere to the listed quantity limits. Exception requests may be submitted per the plan's exception process.

    Drugs that are withdrawn from the market may be removed from the formulary immediately. If a manufacturer withdraws a product or the FDA determines a drug is withdrawn for safety or effectiveness reasons, the plan may remove it without delay and later notify affected members. For other formulary changes made during the year (for example adding a generic or biosimilar, moving a product to a different tier, or adding utilization controls), the plan will provide notice at least 30 days before the change becomes effective or provide a one-time 31‑day supply with notice at the time of refill. Members or prescribers may request an exception to continue covering the prior drug; exception procedures and timelines (standard and expedited) are described elsewhere in the formulary materials.

    The table annotation EX denotes drugs that are not normally covered in a Medicare Prescription Drug Plan. Charges for EX‑listed drugs do not count toward a member's total drug costs (they do not help qualify for catastrophic coverage) and may not qualify for extra help programs.

    Products annotated with EX in the Requirements/Limits column are excluded as indicated on the formulary row. For example, individual product lines such as topical entries or specified strengths that show Requirements/Limits = EX are not covered per the formulary listing and must be treated as excluded when adjudicating claims.

    Within the excerpt provided there are no additional explicit exclusion policy statements beyond the table annotations and legend references. Exclusion status is shown on a per‑product basis through the formulary Requirements/Limits column and the introduction/legend pages explain the annotations.

    An example of a product listed as excluded in the table is SANTYL OINTMENT 250UNIT/GM which appears with formulary row annotations and quantity limits; certain kit and topical product lines are also shown with Requirements/Limits = EX in nearby entries (see table rows for exact items and annotations).

    Examples of items marked EX in the formulary include weight‑loss/anorectic agents such as ADIPEX‑P 37.5MG, various formulations of diethylpropion, and phentermine 37.5MG, which are shown with Requirements/Limits = EX in the table.

    Additional example products flagged EX in the table include select topical and kit products (for example, entries like HYDROCORTISONE ACETATE/PRAMOXINE CREAM 2.5%, PRAMOSONE CREAM, and PROCORT CREAM are shown with Requirements/Limits = EX), indicating exclusion for those specific formulations.

    The formulary shows multiple flagged exclusions. Examples include DRISDOL CAPSULE 50000UNIT listed with Requirements/Limits = EX and other products (for example certain benign prostatic hyperplasia or genitourinary rows) where specific items are indicated as excluded in the Requirements/Limits column.

    Across the table several products are explicitly marked EX. These include erectile dysfunction and genitourinary products where some strengths/formulations show Requirements/Limits = EX (for instance CAVERJECT entries, sildenafil/tadalafil/vardenafil lines) and certain fertility or specialty injectables noted elsewhere with exclusion annotations.

    No items in this excerpt are labeled as Not Medically Necessary (NMN). The formulary excerpt uses annotations such as PA, QL, ST, and EX to indicate utilization controls and exclusions; NMN designations do not appear in the provided segments.

    Coding and Formulary Entries

    Provider Actions and Documentation Requirements

    Prior Authorization

    Provider Actions — Prior Authorization, Quantity Limits, Step Therapy, Documentation

    Many drugs in this formulary require additional provider actions before they will be covered. Review the Requirements/Limits field on the formulary and follow the plan's authorization, quantity, step-therapy, and dispensing rules to avoid claim denials or delays.

    • Prior Authorization (PA): Many specialty, oncology, antineoplastic, high-tier, and select non-specialty drugs are marked PA in Requirements/Limits — an approved prior authorization is required before dispensing (examples: oncology agents marked PA; ARIKAYCE; numerous antineoplastics requiring OVM).
    • Oncology Value Management (OVM): Antineoplastics and oncology supportive-care drugs often require PA through the Oncology Value Management program (OVM/OncoHealth). Providers must submit additional clinical information as specified.
    • Quantity Limits (QL): Numerous drugs include QL entries (e.g., ML/EA per time period). Prescriptions and claims must adhere to these supply limits (examples: buprenorphine products, migraine injectables/tablets, tolvaptan, many others).
    • Step Therapy (ST): Some products are subject to step therapy edits (e.g., select antidepressants, long‑acting injectables, PANCREAZE). Where ST applies, documented trials of required agents must be provided.
    • Network Dispensing / NDS: Certain products indicate NDS or specialty distribution requirements; verify dispensing network or specialty pharmacy requirements before filling (examples: products flagged NDS).
    • Exclusions (EX): Drugs marked EX are not normally covered by the plan and may not count toward catastrophic or extra-help thresholds; do not expect coverage without an approved exception.
    • Denial Risk: Failure to obtain required PA, OVM approval, meet QL limits, or complete ST requirements may result in claim denial or noncoverage.
    • Exception Requests: Prescribers may request exceptions to PA, ST, QL, or formulary tiering. Exception requests must include a supporting medical statement; standard decisions generally issued within 72 hours, expedited (if granted) within 24 hours.
    • Documentation Requirements: Use the Requirements/Limits field to determine required documentation (PA forms, clinical rationale, prior-treatment history, setting/use information for B/D drugs). Include dates, quantities, and supply annotations on submissions.
    • Claims Submission: When PA or other flags apply, include authorization references and required documentation on the claim. Adhere to QL and supply units when calculating days' supply to prevent overrides.
    • Supply and Quantity Enforcement: QL badges specify maximum allowed amounts per period (e.g., EA per 30/90/365 days or ML per period). Requests exceeding QL or lacking PA/OVM approval are subject to denial.
    • PA + QL Interaction: Many specialty agents carry both PA and QL flags — obtain authorization and ensure dispensed quantity is within the allowed limit to avoid denials.
    • Specific Product Examples: Review formulary entries for visible PA/QL/ST/OVM/EX flags (examples shown throughout the formulary — ARIKAYCE PA, many antineoplastics PA; tolvaptan QL+PA; numerous injectables and specialty oral agents PA; select diabetes and weight‑loss injections marked PA and QL).
    • Tier-Based Access: Coverage and cost-sharing depend on tier level; some exceptions may permit coverage at alternate tiers if approved.
    • Operational Note: When a drug is B/D, include information describing the use and setting to determine whether coverage falls under Part B or Part D.
    • Action: Before dispensing, check the formulary Requirements/Limits, confirm PA/OVM/QL/ST/EX status, obtain and document authorizations, and submit required clinical information. Contact the plan or use plan portals for PA/OVM submissions and to verify specialty distribution requirements.

    Background

    This formulary groups drugs by medical condition and uses a standard set of annotations to explain coverage rules. Key formulary terms are defined in the introduction: PA (prior authorization required before fill), QL (quantity limits expressed as units per time period), ST (step therapy), EX (excluded/not normally covered), NDS (non‑extended day supply restrictions), and OVM (Oncology Value Management for antineoplastics). Coverage for a listed drug is contingent on the product's formulary row — tier assignment and any listed Requirements/Limits — and prescribers must follow PA, QL, ST, or exception processes as indicated.

    Definitions and Legend

    inv-104: Generic drug definition
    Generic drugAn FDA‑approved drug with the same active ingredient as the brand‑name drug; generally equivalent in effect and usually lower cost; may be substituted without a new prescription depending on state law.
    Substitution noteGeneric substitutions are subject to state law and pharmacy practices.
    inv-105: Original biological product and biosimilar definition
    Original biological productBiological products are complex drugs; instead of generics they have biosimilars which are alternatives to the original biological product.
    Biosimilar interchangeabilitySome biosimilars are 'interchangeable' and may be substituted per state law without a new prescription.
    inv-106: PA definition (Prior Authorization)
    Prior Authorization (PA)Plan requires approval before filling certain drugs; without approval the plan may not cover the drug.
    Provider actionPrescriber or member must request PA per formulary instructions; failure to obtain PA may result in non‑coverage.
    inv-107: QL definition (Quantity Limit)
    Quantity Limit (QL)A maximum amount of a drug the plan will cover, expressed as units per defined time period (e.g., EA per 31 or 90 days; ML per 30 days).
    FormattingQLs are shown in parentheses after the product (example formatting: QL(360 EA per 90 days)).
    inv-108: ST definition (Step Therapy)
    Step Therapy (ST)The plan may require trying a specified drug first before covering another drug for the same condition.
    Operational impactProducts annotated 'ST' require fulfillment of step edits prior to coverage (see formulary row).
    inv-109: EX definition (Exclusion)
    EX (Exclusion)This prescription drug is not normally covered in a Medicare Prescription Drug Plan; amounts paid do not count toward total drug costs and may not qualify for extra help.
    Table annotationProducts marked EX in the Requirements/Limits column are excluded from coverage per the formulary listing.
    inv-110: NDS definition (Non-Extended Day Supply)
    NDS (Non-Extended Day Supply)Limits supply for certain drugs (example: most opioid analgesics up to 31 days; benzodiazepines up to 30 days).
    ImplicationNDS entries restrict extended (90‑day) fills even if the drug tier otherwise allows 90‑day supply.
    inv-111: OVM definition (Oncology Value Management)
    OVM (Oncology Value Management)Prior authorization program for antineoplastics and oncology supportive care, administered by OncoHealth.
    Provider requirementPhysician must submit additional information for OVM‑managed drugs to determine coverage.
    inv-112: QL (Quantity Limit) definition — examples formatting
    QL examples formattingQuantity limits appear in parentheses using the format QL(<number> <unit> per <days>) e.g., QL(360 EA per 90 days).
    Units usedCommon units include EA (each) and ML (milliliters) depending on formulation.
    inv-113: PA — prior authorization required indicator
    PA indicatorPA annotation in the Requirements/Limits column denotes that prior authorization is required for that product before coverage.
    Denial riskWithout PA approval the plan may not cover the drug — see formulary guidance for PA process.
    inv-114: EX — exclusion indicator
    EX indicator'EX' in Requirements/Limits indicates the product is excluded and not normally covered under Part D.
    Coverage effectPayments for EX items do not count toward total drug costs for catastrophic threshold or extra help qualification.
    inv-115: QL — quantity limit (table legend reference)
    QL table legendQL denotes the maximum units allowed per specified time period as shown in the table (e.g., QL(16 EA per 30 days)).
    ExamplesMany examples appear throughout the formulary rows (EA per 31/90 days; ML per 30/90 days).
    inv-116: PA — provider must obtain approval before coverage
    Provider must obtain approvalPA means the provider must obtain plan approval prior to dispensing for coverage to apply.
    Where shownPA is indicated directly in the Requirements/Limits column for specific products/strengths.
    inv-117: OVM — Oncology Visit Management indicator
    OVM indicatorOVM shown in the Requirements/Limits column identifies drugs requiring Oncology Value Management review (antineoplastics).
    Administrative flowOVM requests are submitted to OncoHealth per formulary instruction to determine coverage.
    inv-118: PA definition (additional occurrences)
    PA (definition restated)Prior Authorization — coverage approval required prior to dispensing for specified drugs.
    Table annotationPA appears in Requirements/Limits next to products that need authorization.
    inv-119: QL definition (additional occurrences)
    QL (definition restated)Quantity Limit — the plan limits the amount it will cover for certain drugs, shown as QL(number unit per days).
    Use in claimsClaims exceeding QL may be denied or require PA/exception to cover additional quantity.
    inv-120: OVM definition (additional occurrences)
    OVM (definition restated)Other Vendor/Oncology Value Management — formulary flag for oncology agents requiring specialized authorization and review.
    Effect on coverageDrugs flagged OVM require submission of clinical details to OncoHealth to determine coverage eligibility.
    inv-121: ST definition (additional occurrences)
    ST (definition restated)Step Therapy — the plan requires trial of specified first‑line drug(s) before covering alternatives; products annotated 'ST' are subject to step edits.
    ExamplesEXXUA, certain long‑acting injectables and select oral agents are shown with ST in Requirements/Limits.
    inv-122: QL / PA / EX / B/D legend summary
    Legend summaryQL denotes quantity limit; PA denotes prior authorization; EX denotes excluded; B/D indicates Part B/Part D determination may be required.
    Refer to introductionSee formulary introduction pages for full symbol/abbreviation legend and operational details.
    inv-123: QL (Quantity Limit) — legend reference
    QL — table referenceQuantity Limit entries are shown in parentheses after products as QL(number unit per period) and indicate the plan's maximum covered amount.
    Units and periodsExamples use EA (each) and ML (milliliters) over 31/30/90/365 day periods.
    inv-124: PA — legend reference (table annotation)
    PA — table annotation'PA' in Requirements/Limits indicates prior authorization is required before coverage is approved.
    Operational noteProviders should follow PA procedures to avoid claim denials for PA‑flagged drugs.
    inv-125: EX — legend reference (table annotation)
    EX — table annotation'EX' in Requirements/Limits marks excluded products that are not normally covered under Part D.
    Financial impactPayments for EX items do not count toward total drug costs or eligibility for catastrophic coverage/extra help.

    Step Therapy Rules

    Coverage labelSummary
    Covered
    Must try specified first-line drugs before covering alternative drugs for the same condition (step therapy may require trial of Drug A before covering Drug B).
    Coverage labelSummary
    Covered
    Some drugs are subject to step therapy (ST) requiring trial of specified drug(s) before coverage of alternatives; see formulary row 'ST' annotation.
    Coverage labelSummary
    neutral
    No explicit step therapy algorithms specified in these segments; primary utilization controls are tier assignment, quantity limits (QL), and prior authorization (PA) flags.
    Coverage labelSummary
    Covered
    EXXUA products (titration pack and tablets) are annotated with ST; step therapy requirements apply as shown in formulary rows (QL and ST present).
    Coverage labelSummary
    Covered
    Products annotated 'ST' require fulfillment of step edits prior to coverage; examples in the formulary include EXXUA, TRINTELLIX, and FETZIMA where ST appears alongside QL entries.
    Coverage labelSummary
    neutral
    Not specified in these excerpts (no additional step therapy details provided).
    Coverage labelSummary
    Covered
    Step therapy (ST) is noted for certain long-acting injectable antipsychotics (e.g., ARISTADA, INVEGA products) — ST flag present though specific required prior therapies are not shown here.
    Coverage labelSummary
    neutral
    PAXLOVID therapy pack entries list multiple QL values for different pack configurations; no explicit step therapy edits are documented in these chunks.
    Coverage labelSummary
    neutral
    Specialty hematology agents are frequently subject to prior authorization (PA) and OVM; step therapy requirements are not explicitly detailed in these excerpts.
    Coverage labelSummary
    Covered
    FARXIGA and JARDIANCE formulary entries include 'ST' alongside QL, indicating that step therapy requirements apply for these SGLT2 inhibitors.
    Coverage labelSummary
    Covered
    PANCREAZE product lines are marked 'ST' in the formulary, indicating a step therapy requirement for those pancreatic enzyme products.

    Quantity Limits (QL) by Product

    Revision History

    2026-06-01policy effective/last updatedLatest

    Formulary pages display Effective Date and Last Updated as 06/01/2026; legends and abbreviations referenced on introduction pages.

    2026-06-01table-level annotations updated

    Multiple cardiovascular and CNS drug table rows show Requirements/Limits and QL/ST/EX annotations with Effective Date and Last Updated 06/01/2026.